CAS |
No.39011-91-1 |
中文名称 |
氧化芍药苷 |
英文名称 |
Oxypaeoniflorin |
别名 |
羟基芍药苷 |
分子式 |
C23H28O12 |
分子量 |
496.46 |
溶解性 |
Soluble in DMSO |
纯度 |
HPLC≥98% |
级别 |
Cell Culture |
外观(性状) |
White to off-white Solid |
储存条件 |
Powder:2-8℃,2 years;Insolvent(母液):-20℃,6 months;-80℃,1 year |
运输条件 |
冷藏运输 |
MDL |
MFCD00869478 |
SMILES |
O=C(C1=CC=C(O)C=C1)OC[C@]([C@@]([C@]2(O)O3)([H])C4)([C@]3([H])O[C@]5(C2)C)[C@]45O[C@]([C@@H]([C@@H](O)[C@@H]6O)O)([H])O[C@@H]6CO |
InChIKey |
FCHVXNVDFYXLIL-WRJNSLSBSA-N |
InChI |
InChI=1S/C23H28O12/c1-20-8-22(30)13-6-23(20,33-18-16(28)15(27)14(26)12(7-24)32-18)21(13,19(34-20)35-22)9-31-17(29)10-2-4-11(25)5-3-10/h2-5,12-16,18-19,24-28,30H,6-9H2,1H3/t12-,13-,14-,15+,16-,18+,19-,20+,21+,22-,23+/m1/s1 |
PubChem CID |
21631105 |
靶点 |
Others |
通路 |
Others |
背景说明 |
是一种具有抗氧化活性的单萜糖苷化合物,可用于神经保护和抗炎作用的研究。 |
生物活性 |
Oxypaeoniflorin, an anti-oxidant, is a monoterpene glycoside compound isolated from Paeoniae species. Oxypaeoniflorin has neuroprotective and anti-inflammatory effects[1][2]. |
In Vitro |
Oxypaeoniflorin (OPA; 0.1-10 μM; 8 hours) obviously reversed the hypoxia/reoxygenation (H/R)-induced decrease in cell activity and increase in apoptosis of H9c2 cells. Oxypaeoniflorin inhibits apoptosis by activating the Sirt1 (silent information regulator factor 2 related enzyme 1)/Foxo1(forkhead transcription factor FKHR) signaling pathway in myocardial tissues and H9c2 cells[1].Oxypaeoniflorin (0-30 μM) attenuates inflammatory effects via regulation of the toll-like receptor (TLR), extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases signaling pathways in LPS-stimulated RAW264.7 cells[2]. |
In Vivo |
Oxypaeoniflorin (OPA; 10-40 mg/kg; intragastrical administration; every day; for 30 days) treatment significantly reduces disruption of cardiac function and improves the indicators of ejection fraction (EF) and fractional shortening (FS). Oxypaeoniflorin significantly reduces the release of myocardial infarction-related factors, such as the creatine kinase (CK-MB), cardiac troponin I (cTnI) and cardiac troponin T (cTnT)[1].Animal Model: C57BL/6 male mice (6-8 weeks of age, 20-25 g) bearing myocardial ischemia/reperfusion (MI/R) injury[1];Dosage:10 mg/kg, 20 mg/kg, 40 mg/kg;Administration:Intragastrical administration; every day; for 30 days;Result:Significantly reduced disruption of cardiac function and improved the indicators of ejection fraction (EF) and fractional shortening (FS). |
数据来源文献 |
[1]. Kai Wang, et al. Oxypaeoniflorin improves myocardial ischemia/reperfusion injury by activating the Sirt1/Foxo1 signaling pathway. Acta Biochim Pol. 2020 Jun 18;67(2):239-245. [2]. Feng C, et al. Pharmacokinetic properties of paeoniflorin, albiflorin and oxypaeoniflorin after oral gavage of extracts of Radix Paeoniae Rubra and Radix Paeoniae Alba in rats. J Ethnopharmacol. 2010 Jul 20;130(2):407-13. |
规格 |
1mg 5mg 10mg |
单位 |
瓶 |